LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassay Detects Five Encephalitis Viruses

By LabMedica International staff writers
Posted on 05 Jul 2012
An enzyme-linked immunosorbent assay (ELISA) array had been developed that will detect five different encephalitis viruses.

The ELISA-array assay is based on a sandwich ELISA format and consists of viral antibodies printed directly on 96-well microtiter plates, allowing for direct detection of five Arboviruses.

Virologists at the Institute of Microbiology and Epidemiology (Beijing, China) prepared monoclonal antibodies against five viruses: Japanese encephalitis virus (JEV), Tick-borne encephalitis virus (TBEV), Eastern equine encephalitis virus (EEEV), Sindbis virus (SV), and Dengue virus (DV). Antibodies were spotted using a BD6000 machine on ELISA plates at 30 nL/dot. Seven monoclonal antibodies against five encephalitis-associated viruses were prepared and used for development of the ELISA-array. Identical antibodies used in the ELISA-array format were also tested in a conventional ELISA format to determine the difference in sensitivity and specificity of the two methods.

The detection limit of the two methods was compared and demonstrated. The cross-reactivity test was conducted using BHK-21 and Vero cell lysate, Yellow fever virus (YFV) cultures, West Nile virus (WNV) cultures, and Western equine encephalitis virus. The results demonstrated that neither the ELISA-array nor traditional ELISA displayed cross-reactivity. Equal volumes of cultured TBEV, JEV, DV-2, DV-4, SV, and EEEV were prepared for single sample detection; two or three of the cultures were mixed for multiplex detection. The BD6000 dot machine is manufactured by BioDot (Irvine, CA, USA)

The authors concluded that the developed ELISA-array proved to have similar specificity and higher sensitivity compared with the conventional ELISAs. This method was validated by different viral cultures and three chicken eggs inoculated with infected patient serum. The results demonstrated that the developed ELISA-array is sensitive and easy to use, which would have potential for clinical use. The four hours time required for the ELISA-array is significantly less than for conventional ELISA. With the characteristics of ease of use, sensitivity, specificity, and accuracy, the ELISA-array assay would be widely accepted for clinical use. The study has been available online since February 27, 2012, in the Virology Journal.

Related Links:

Institute of Microbiology and Epidemiology
BioDot



Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
Repetitive Pipette
VWR® Stepper Pro

Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
ADLM